Le terapie farmacologiche nelle fratture da fragilità
- First Online:
Drug therapy in osteoporotic fractures
Many therapeutic agents are currently available for osteoporotic fractures prevention, and their efficacy has been demonstrated in several clinical studies. Major evidences derive from randomized controlled trials or meta-analyses in which vertebral, non-vertebral and hip antifracture effect was tested. Here we summarize the principal data about drugs currently registered in Italy for the treatment of osteoporosis.
- 9.Rossouw JE, Anderson GL, Prentice RL et al; Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333PubMedCrossRefGoogle Scholar
- 10.Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637–645PubMedCrossRefGoogle Scholar
- 12.Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348: 1535–1541Google Scholar
- 23.Reginster JY, Felsenberg D, Boonen S et al (2008) Effects of longterm strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 58:1687–1695PubMedCrossRefGoogle Scholar